https://www.selleckchem.com/pr....oducts/acetosyringon
Further inhibition of CHD1L and its downstream autophagy signaling might shed new light on cancer therapeutics.BACKGROUND Bladder cancer (BC) is the second most common cancer involving the urinary system. In non-muscle-invading BC, transurethral resection of a bladder tumor followed by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) is the usual treatment. Disseminated (or systemic) BCG infection (BCGitis) represents the most severe adverse effect of intravesical BCG therapy, presenting with high-grade fever, with
Like
Comment
Share
